The Science of Psilocybin.
And Beyond.
Deep psilocybin neuroscience — receptor binding, neuroplasticity, clinical protocols, veteran restoration — plus research on other psychedelic compounds. Published daily. Every claim backed by peer-reviewed data.
Featured Articles
The Waking Dream
The oldest word for a trip is ‘dreamlike’ — and the neuroscience runs deeper than metaphor. Serotonin normally promotes waking and suppresses REM sleep (Monti 2011); a 5-HT2A agonist reduces both REM and slow-wave sleep in animals (Monti & Jantos 2006). Yet in humans, daytime ayahuasca reduced REM and boosted deep slow-wave sleep without disrupting the night (Barbanoj et al. 2008), and psilocybin delayed REM onset much like a classical antidepressant (Dudysová et al. 2020)…
The Other Door
Almost every classic psychedelic works through one receptor — serotonin 5-HT2A. Salvia divinorum is the great exception. Its molecule, salvinorin A, is a potent and selective agonist of the kappa opioid receptor (Roth et al. 2002) — a completely different doorway to altered consciousness. In humans, the opioid blocker naltrexone abolishes its effects while the serotonin blocker ketanserin does not (Maqueda et al. 2016), proving the mechanism…
The Chemistry of Connection
MDMA’s signature is closeness — and a large part of it is one ancient molecule. MDMA triggers a robust release of oxytocin, and in humans the rise in oxytocin tracks the rise in prosocial feeling more closely than blood MDMA itself (Dumont et al. 2009). In animals, blocking oxytocin blunts MDMA’s sociability, and the release runs through 5-HT1A receptors on oxytocin neurons (Thompson et al. 2007). A single dose can even reopen a critical period for social reward learning (Nardou et al. 2019)…
The Inflamed Mind
Depression may be, in part, an inflamed brain — and psychedelics are turning out to be startlingly potent anti-inflammatories. Activating the 5-HT2A receptor blocks TNF-α-driven inflammation at picomolar doses (Yu et al. 2008), an effect that holds in living animals (Nau et al. 2013). Psilocin quiets the brain’s own immune cells, the microglia, dialing down their reactive oxygen species and phagocytosis in a 5-HT2-dependent way (Kozłowska et al. 2024)…
The Growing Brain
Depression physically shrinks the brain’s connections - dendritic spines wither under chronic stress. This deep dive covers how psychedelics do the opposite: a single dose grows new spines and synapses, some more potently than ketamine (Ly et al. 2018), one dose of psilocybin raises spines ~10% in the frontal cortex for a month (Shao et al. 2021), and the new spines are needed for the sustained antidepressant effect (Moda-Sava et al. 2019)…
The Other Receptor
The 5-HT2A receptor gets the credit for the psychedelic trip - but its quieter sibling, 5-HT2C, is a counterweight. This deep dive covers how it edits its own RNA into many forms (Burns et al. 1997), tonically restrains dopamine even without serotonin bound (De Deurwaerdère et al. 2004), and modulates and can dampen the 2A-driven response (Fantegrossi et al. 2010) - a balance struck across a receptor family, not one switch…
The Wandering Nerve
The vagus nerve is the body’s great wandering highway - the main channel of the parasympathetic ‘rest and digest’ system. This deep dive covers what it does: it sets the calm of the social-engagement state (Porges 2007), tunes heart-rate variability and emotion (Thayer & Lane 2000), and even quiets inflammation through the cholinergic anti-inflammatory pathway (Tracey 2002) - and where it meets the psychedelic state…
The Surprise Signal
Dopamine is not the molecule of pleasure - it is the molecule of surprise. This deep dive covers how dopamine neurons fire not when reward arrives but when it arrives unexpectedly, broadcasting a reward prediction error that teaches the brain (Schultz, Dayan & Montague 1997). When that signal goes quiet the world loses its shine - anhedonia (Der-Avakian & Markou 2012) - and psychedelics may help restore it (Hesselgrave et al. 2021)…
The 40-Hertz Mind
How does the brain bind scattered features into one unified experience? This deep dive covers gamma - fast ~40 Hz oscillations that synchronize distant neurons (Gray & Singer 1989), are paced by parvalbumin interneurons (Cardin et al. 2009; Sohal et al. 2009), and track conscious perception itself (Melloni et al. 2007) - and what psychedelics do to the brain’s fastest rhythm…
The Body's Own Cannabis
Your brain makes its own cannabis. This deep dive covers the endocannabinoid system - anandamide and 2-AG acting on CB1 receptors (Devane et al. 1992; Matsuda et al. 1990), a system that runs backwards across the synapse to dial down its own inputs (Wilson & Nicoll 2001), tunes fear and memory (Marsicano et al. 2002), and produces the runner’s high (Fuss et al. 2015)…
The Switch
Deep in the brain sits a switch that decides what deserves your attention. This deep dive covers the salience network - anchored in the anterior insula and dorsal anterior cingulate (Seeley et al. 2007) - which detects what matters and toggles the mind between inward, self-focused thought and outward, task-focused action (Menon & Uddin 2010; Sridharan et al. 2008). When the switch gets stuck, disorders follow - and psychedelics may work partly by loosening it (Tagliazucchi et al. 2016)…
The Editable Memory
Memories are not permanent recordings. This deep dive covers reconsolidation - when you recall a memory it briefly becomes unstable and must be re-saved (Nader, Schafe & LeDoux 2000), a window in which it can be weakened with a beta-blocker (Kindt 2009), updated with new learning (Schiller 2010), or - the frontier - revisited under MDMA so a trauma can be re-stored stripped of its terror (Feduccia & Mithoefer 2018)…
Precision-dosed psilocybin
mushroom products.
Engineered for daily ritual, neural reconstruction, and sustained cognitive performance. Lab-tested. Ceremony-ready.
Shop OOTW · 10% Off With Code JOURNAL10About Out Of This World
We operate at the threshold where ancient plant wisdom meets modern clinical observation. OOTW JOURNAL exists because psilocybin science deserves a dedicated platform — one that treats the research with the seriousness it demands. No hype. No speculation. Only mechanisms, clinical data, and protocols.
Our primary focus is psilocybin: receptor pharmacology, neuroplasticity, BDNF expression, veteran restoration, daily microdosing protocols. We also cover adjacent psychedelic compounds and consciousness research. New articles published daily. Every claim backed by peer-reviewed data.
Shop OOTW · 10% Off With Code JOURNAL10 open_in_new